Prolonged enhancement of cytotoxic T lymphocytes in the post-recovery state of severe COVID-19

Table 1 Patient characteristics

	Hospitalized patients^b			Recovered patients			Healthy donors
	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Donor 1	Donor 2	Donor 3	Donor 4
Age, years	75	85	73	67	57	62	65	62	71	70
Sex	Female	Male	Male	Male	Male	Female	Female	Female	Male	Male
Body mass index, kg/m²	20.5	22.7	20.9	24.5	23	29.1	18.7	18.6	21.4	26.9
Past medical history	None	HT	None	DM	None	None
Clinical features at admission
Severity of ARDS^a	Moderate	Severe	Severe	Moderate	Severe	Severe
APACHE II score	18	17	20	10	9	16
Disease course
ECMO	−	−	−	−	+	+
Tracheostomy	+	+	+	+	−	−
Length of stay in ICU, days	37	29	45	27	17	18
Days of mechanical ventilation, days	42	37	45	34	16	17
Length of stay in hospital, days	156	141	187	92	31	67
Discharge	Nursing home	Home	Home	Home	Home	Home
Days from hospitalization to specimen	100	103	98	105	95	87

ARDS acute diffuse respiratory syndrome, APACHE acute physiology and chronic health evaluation, ECMO extracorporeal membranous oxygenation, ICU intensive care unit, DM diabetes mellitus, HT hypertension
^aSevere: 100 ≤ PaO₂/FiO₂, moderate: 100 < PaO₂/FiO₂ ≤ 200 (on positive end-expiratory pressure of 5 cmH₂O)
^bPatients who were hospitalized at the time of blood sample collection

ISSN: 2052-0492